Medline Inc. (MDLN)
MDLN trades on Nasdaq in Health Care, Medical/Dental Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/2046386/000204638626000009/0002046386-26-000009-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | MDLN on Nasdaq |
| Sector | Health Care |
| Industry | Medical/Dental Instruments |
| Country | United States |
| IPO year | 2025 |
| SEC CIK | 0002046386 |
| SEC industry code | Surgical & Medical Instruments & Apparatus |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $28.4B |
| Net income | $1.2B |
| Operating income | $2.2B |
| Net margin | 4.1% |
| Operating margin | 7.8% |
| Revenue growth | +11.5% |
| Cash | $1.9B |
| Total assets | $38.5B |
| P/E (computed) | 44.5× |
| P/S (computed) | 1.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $2.3B cash; operating cash flow $595.3M a quarter. | Report 2026-09-26 |
| Shares outstanding | 1,315,321,434 (2026-11-02). | Cover page 2026-11-02 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Chicago, Illinois, United States | PCAOB Form AP 2026-03-16 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $515.0M, sold $7.2B on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-26 | $7.9B | $318.0M | $1.0B | $2.3B | $12.6B | $30.7B | 10-Q 2026-11-04 |
| Q2 2026 2026-06-27 | $7.7B | $139.0M | $715.0M | $2.3B | $12.6B | $29.9B | 10-Q 2026-08-05 |
| Q1 2026 2026-03-28 | $7.4B | $239.0M | $412.0M | $2.2B | $12.6B | $29.1B | 10-Q 2026-05-06 |
| Q4 2025 2025-12-31 | $7.8B | $193.0M | $229.0M | $1.9B | $12.6B | $28.4B | 10-K 2026-02-25 |
| Q3 2025 2025-09-27 | $7.1B | $318.0M | $636.0M | $955.0M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q2 2025 2025-06-28 | $6.9B | $329.0M | $197.0M | $584.0M | No debt tags | Needs four quarters | 10-Q 2026-08-05 |
| Q1 2025 2025-03-29 | $6.6B | $319.0M | $682.0M | $840.0M | No debt tags | Needs four quarters | 10-Q 2026-05-06 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-1 | 2026-11-16 |
| Latest annual report | 10-K | 2026-02-25 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-04-23 |
Source: SEC EDGAR submissions feed, 168 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -0.4% |
| 1 month | +10.6% |
| 3 months | +10.9% |
| Year to date | -6.0% |
| 1 year | Not enough price history |
| From 52-week high | -21.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medical/Dental Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BDX | Becton Dickinson and Company | $216.47 | -0.72% | $59.0B |
| BSX | Boston Scientific Corporation | $43.69 | -1.47% | $63.3B |
| RMD | ResMed Inc. | $238.19 | -0.56% | $33.5B |
| DXCM | DexCom Inc. | $81.61 | -2.06% | $30.4B |
| WST | West Pharmaceutical Services Inc. | $417.80 | +0.33% | $29.1B |
| MMM | 3M Company | $181.68 | -1.08% | $93.9B |
| SYK | Stryker Corporation | $310.72 | +0.35% | $118.3B |
| SOLV | Solventum Corporation | $88.65 | -0.48% | $15.0B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier